| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2019-03-20 | Flagship Pioneering (USA - MA) | $824 million | financing round | undisclosed long-time limited partners, new institutional investors, family offices | Financing round | |
| 2019-03-11 | Snipr Biome (Denmark) | $50 million (€43 million, DKK320 million) | series A financing round | Lundbeckfonden Emerge (Denmark) LSP (Netherlands) North-East Family Office (Denmark) Wellington Partners (Germany) | Autoimmune diseases - Cancer - Oncology - Infectious diseases | Series A financing round |
| 2019-03-06 | Beam Therapeutics (USA - MA) | $135 million | series B financing round | ARCH Venture Partners (USA - IL) F-Prime Capital Partners (USA - MA) Eight Roads Ventures (China - India - USA) Omega Funds (USA - MA) Redmile Group (USA - CA) Cormorant Asset Management (USA - MA) GV (USA - CA) Altitude Life Science Ventures (USA - WA) and additional undisclosed investors | Rare diseases - Genetic diseases | Series B financing round |
| 2019-02-27 | MeiraGTx (USA - NY) | $80 million | private placement | Johnson & Johnson Innovation – JJDC (USA - NJ) Perceptive Advisors (USA - NY) OrbiMed Advisors, (USA - NY) 683 Capital Management (USA - NY) | Rare diseases - Genetic diseases | Private placement |
| 2019-02-14 | Passage Bio (USA - PA) | $115.5 million | series A financing round | OrbiMed Advisors (USA - NY) Frazier Healthcare Partners (USA - WA) Versant Ventures (USA - CA) New Leaf Venture Partners (USA - NY - CA) Vivo Capital (USA - CA) Lilly Asia Ventures (China) | Rare diseases - Genetic diseases - CNS diseases | Series A financing round |
| 2019-02-12 | Neurogene (USA - NY) | $68.5 million | series A financing round | Samsara BioCapital (USA - CA) EcoR1 Capital (USA - CA) Cormorant Asset Management (USA - MA) Redmile Group (USA - CA) undisclosed leading healthcare investment fund. | Rare diseases - Genetic diseases - Neurological diseases | Series A financing round |
| 2019-01-25 | Nordic Nanovector (Norway) | NOK 222 million ($ 26 million) | private placement | Cancer - Oncology | Private placement | |
| 2019-01-25 | Corbus Pharmaceuticals (USA - MA) | private placement | Inflammatory diseases | Private placement | ||
| 2019-01-24 | Wave Life Sciences (USA - MA) | $150 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2019-01-24 | Wave Life Sciences (USA - MA) | $150 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2019-01-23 | Orion (Finland) | € 100 million | loan | European Investment Bank (EIB) | Cancer - Oncology - Neurological diseases - Respiratory diseases | Loan |
| 2019-01-23 | PTC Therapeutics (USA - NJ) | private placement | Rare diseases - Genetic diseases | Private placement | ||
| 2019-01-23 | Selecta Biosciences (USA - MA) | $30 million | private placement | Private placement | ||
| 2019-01-22 | Alvotech (Iceland) | $300 million | private placement | Autoimmune diseases - Inflammatory diseases - Cancer - Oncology | Private placement | |
| 2019-01-14 | Alnylam Pharmaceuticals (USA - MA) | $387.5 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2019-01-04 | Aimmune Therapeutics (USA - CA) | $ 170 million | loan | KKR (USA - NY) | Allergic diseases | Loan |
| 2019-01-03 | Cabaletta Bio (USA - PA) | $50 million | series B financing round | Adage Capital (USA - MA) 5AM Ventures (USA - MA) Deerfield Management Company (USA - NY) Boxer Capital of Tavistock Group (Bahamas) Redmile Group (USA - CA) Cormorant Capital (USA - IL) | Autoimmune diseases | Series B financing round |
| 2018-12-21 | Nabriva Therapeutics (Ireland) | $75 million | loan | Hercules Capital (USA - CA) | Infectious diseases | Loan |
| 2018-12-20 | Geneuro (Switzerland) | €7.5 million | credit line | GNEH (France) | Neurodegenerative diseases | Loan |
| 2018-12-19 | Altheia Science (Italy) | $19.3 million (€17 million) | series A financing round | Fin Posillipo SpA, holding company of Petrone Group (Italy) the Rovati family’s Fidim (Italy) Rottapharm Biotech (Italy) undisclosed seasoned private players with successful track record in the biotech sector | Autoimmune diseases - Cancer - Oncology | Series A financing round |
